

# Gale Smith

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5498095/publications.pdf>

Version: 2024-02-01

28  
papers

3,376  
citations

331670

21  
h-index

501196

28  
g-index

37  
all docs

37  
docs citations

37  
times ranked

5934  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 73-84.	9.1	35
2	Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine. <i>Clinical Infectious Diseases</i> , 2021, 73, e4278-e4287.	5.8	23
3	Structural Characterization and Modeling of a Respiratory Syncytial Virus Fusion Glycoprotein Nanoparticle Vaccine in Solution. <i>Molecular Pharmaceutics</i> , 2021, 18, 359-376.	4.6	12
4	SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. <i>Nature Communications</i> , 2021, 12, 372.	12.8	369
5	Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. <i>New England Journal of Medicine</i> , 2021, 384, 2352-2354.	27.0	202
6	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. <i>Cell Reports Medicine</i> , 2021, 2, 100405.	6.5	110
7	Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2020, 222, 572-582.	4.0	38
8	Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge. <i>Vaccine</i> , 2020, 38, 1258-1270.	3.8	9
9	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. <i>Science</i> , 2020, 370, 1089-1094.	12.6	290
10	Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity. <i>Vaccines</i> , 2020, 8, 607.	4.4	8
11	Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, 2320-2332.	27.0	1,000
12	NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. <i>Vaccine</i> , 2020, 38, 7892-7896.	3.8	200
13	Influenza Hemagglutinin Nanoparticle Vaccine Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA. <i>Vaccines</i> , 2020, 8, 99.	4.4	24
14	Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection. <i>Vaccine</i> , 2019, 37, 6112-6124.	3.8	25
15	Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein. <i>PLoS ONE</i> , 2019, 14, e0210749.	2.5	7
16	Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. <i>Vaccine</i> , 2018, 36, 8069-8078.	3.8	24
17	Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine. <i>New England Journal of Medicine</i> , 2018, 378, 2346-2348.	27.0	45
18	Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M, $\alpha$ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes. <i>Vaccine</i> , 2017, 35, 5366-5372.	3.8	44

#	ARTICLE	IF	CITATIONS
19	Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models. <i>Vaccine</i> , 2017, 35, 4079-4087.	3.8	12
20	Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults. <i>Immunity and Ageing</i> , 2017, 14, 8.	4.2	62
21	Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle. <i>Scientific Reports</i> , 2016, 6, 24897.	3.3	35
22	Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. <i>Vaccine</i> , 2016, 34, 1927-1935.	3.8	106
23	A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. <i>Journal of Infectious Diseases</i> , 2016, 213, 411-422.	4.0	130
24	Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs. <i>Vaccine</i> , 2015, 33, 6488-6492.	3.8	27
25	Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. <i>Vaccine</i> , 2013, 31, 524-532.	3.8	118
26	Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats. <i>PLoS ONE</i> , 2012, 7, e50852.	2.5	131
27	Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. <i>Vaccine</i> , 2011, 29, 6606-6613.	3.8	85
28	Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. <i>Vaccine</i> , 2007, 25, 4283-4290.	3.8	86